Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. RNLX.NASDAQ

Renalytix AI (RNLX NASDAQ) stock market data APIs

$0.3064 -0.05(-14.2%) as of July 26, 2024
Price chart is built with Anychart

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.

Renalytix AI Financial Data Overview

0.3515
0.3064
-
0.37
0.3064
0.22-3.14
28 896 K
82 963 K
2 221 K
-0.08
2.099
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'RNLX',
Type: 'Common Stock',
Name: 'Renalytix AI',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00VPNC562',
ISIN: NULL,
CUSIP: NULL,
CIK: '1811115',
EmployerIdNumber: NULL,
FiscalYearEnd: 'June',
IPODate: '2020-07-17',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Health Information Services',
HomeCategory: 'ADR',
IsDelisted: false,
}

Renalytix AI Fundamental Data is available in our Financial Data APIs

  • Net Revenue 2 221 K
  • EBITDA -33 070 000
  • Earnings Per Share -0.76
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Renalytix AI Earnings via APIs

  • Latest Release 2024-05-15
  • EPS/Forecast -0.07

Get Renalytix AI End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Renalytix AI latest news via APIs

New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease

Renalytix plc Electronic health record deployment of KidneyIntelX was associated with clinical actions that slowed progression of chronic kidney disease and improved Type 2 diabetes control in just 1...

Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024

Renalytix plc LONDON and SALT LAKE CITY, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimi...
Do you have any questions?
support@eodhistoricaldata.com